Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound.

The drugmaker said Thursday it will use the site, called LillyDirect, to pair visitors with third-party mail-order pharmacies for prescriptions and to care providers through a virtual medical weight-loss clinic.

The site also offers a directory for in-person care and help with insulins and migraine treatments.

Lilly says the doctors connected through the website are independent and not paid to promote its products, and the drugmaker also isn’t paid to send referrals to them.

In November, U.S. regulators approved Zepbound, a version of the popular diabetes treatment Mounjaro, to be used as a weight-loss treatment. The drug joins Novo Nordisk’s Wegovy in a hot field for care, chronic weight management.